Literature DB >> 27471056

Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.

M Johanneke van den Berg1, Yolanda van der Graaf2, Gert Jan de Borst3, L Jaap Kappelle4, Hendrik M Nathoe5, Frank L J Visseren6.   

Abstract

Low-density lipoprotein cholesterol (LDL-C) only partly represents the atherogenic lipid burden, and a growing body of evidence suggests that non-high-density lipoprotein cholesterol (non-HDL-C), triglycerides, and apolipoprotein B (apoB) are more accurate in estimating lipid-related cardiovascular disease risk. Our objective was to compare the relation among LDL-C, non-HDL-C, triglycerides, and apoB and the occurrence of future vascular events and mortality in patients with manifest arterial disease. This is a prospective cohort study of 7,216 patients with clinically manifest arterial disease in the Secondary Manifestations of Arterial Disease Study. Cox proportional hazard models were used to quantify the risk of major cardiovascular events (MACE; i.e., stroke, myocardial infarction, and vascular mortality) and all-cause mortality. Interaction was tested for type of vascular disease at inclusion. MACE occurred in 1,185 subjects during a median follow-up of 6.5 years (interquartile range 3.4 to 9.9 years). Adjusted hazard ratios (HRs) of MACE per 1 SD higher were for LDL-C (HR 1.15, 95% confidence interval [CI] 1.09 to 1.22), for non-HDL-C (HR 1.17, 95% CI 1.11 to 1.23), for log(triglycerides) (HR 1.12, 95% CI 1.06 to 1.19), and for apoB HR (1.12, 95% CI 0.99 to 1.28). The relation among LDL-C, non-HDL-C, and cardiovascular events was comparable in patients with cerebrovascular disease, coronary artery disease, or polyvascular disease and absent in those with aneurysm of abdominal aorta or peripheral artery disease. In conclusion, in patients with a history of cerebrovascular, coronary artery, or polyvascular disease, but not aneurysm of abdominal aorta or peripheral artery disease, higher levels of LDL-C and non-HDL-C are related to increased risk of future MACE and of comparable magnitude.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27471056     DOI: 10.1016/j.amjcard.2016.06.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Effect of adding bezafibrate to standard lipid-lowering therapy on post-fat load lipid levels in patients with familial dysbetalipoproteinemia. A randomized placebo-controlled crossover trial.

Authors:  Charlotte Koopal; A David Marais; Jan Westerink; Yolanda van der Graaf; Frank L J Visseren
Journal:  J Lipid Res       Date:  2017-09-19       Impact factor: 5.922

2.  Association of Lipids, Lipoproteins, and Apolipoproteins with Stroke Subtypes in an International Case Control Study (INTERSTROKE).

Authors:  Martin J O'Donnell; Matthew McQueen; Allan Sniderman; Guillaume Pare; Xingyu Wang; Graeme J Hankey; Sumathy Rangarajan; Siu Lim Chin; Purnima Rao-Melacini; John Ferguson; Denis Xavier; Liu Lisheng; Hongye Zhang; Prem Pais; Patricio Lopez-Jaramillo; Albertino Damasceno; Peter Langhorne; Annika Rosengren; Antonio L Dans; Ahmed Elsayed; Alvaro Avezum; Charles Mondo; Conor Judge; Hans-Christoph Diener; Danuta Ryglewicz; Anna Czlonkowska; Nana Pogosova; Christian Weimar; Romana Iqbal; Rafael Diaz; Khalid Yusoff; Afzalhussein Yusufali; Aytekin Oguz; Ernesto Penaherrera; Fernando Lanas; Okechukwu S Ogah; Adesola Ogunniyi; Helle K Iversen; German Malaga; Zvonko Rumboldt; Shahram Oveisgharan; Fawaz Al Hussain; Yongchai Nilanont; Salim Yusuf
Journal:  J Stroke       Date:  2022-05-31       Impact factor: 8.632

3.  Associations of Socioeconomic Status and Healthy Lifestyle With Incidence of Dyslipidemia: A Prospective Chinese Governmental Employee Cohort Study.

Authors:  Ling Li; Feiyun Ouyang; Jun He; Dan Qiu; Dan Luo; Shuiyuan Xiao
Journal:  Front Public Health       Date:  2022-06-09

4.  Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity.

Authors:  Sha Li; Yuan-Lin Guo; Xi Zhao; Yan Zhang; Cheng-Gang Zhu; Na-Qiong Wu; Rui-Xia Xu; Ping Qing; Ying Gao; Xiao-Lin Li; Jing Sun; Geng Liu; Qian Dong; Jian-Jun Li
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

5.  Targeted proteomics for evaluating risk of venous thrombosis following traumatic lower-leg injury or knee arthroscopy.

Authors:  Yassene Mohammed; Carolina E Touw; Banne Nemeth; Raymond A van Adrichem; Christoph H Borchers; Frits R Rosendaal; Bart J van Vlijmen; Suzanne C Cannegieter
Journal:  J Thromb Haemost       Date:  2022-01-06       Impact factor: 16.036

Review 6.  Mass Spectrometry for the Monitoring of Lipoprotein Oxidations by Myeloperoxidase in Cardiovascular Diseases.

Authors:  Catherine Coremans; Cédric Delporte; Frédéric Cotton; Phillipe Van De Borne; Karim Zouaoui Boudjeltia; Pierre Van Antwerpen
Journal:  Molecules       Date:  2021-08-30       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.